Changchun High-tech (000661.SZ) subsidiary GenSci143 obtained approval for overseas production drug registration clinical trial application for injectable drugs.

The China Securities and Finance app reports that Changchun High-tech (000661.SZ) has released an announcement. Recently, the company's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received written notification from the Food and Drug Administration (FDA) of the United States. Jinsai Pharmaceutical's application for clinical trials of injection GenSci143 has been approved.